Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 35Neoplasms 32Parkinson Disease 4, Autosomal Dominant Lewy Body 26Multiple Myeloma 24Leukemia, Myeloid, Acute 21Recurrence 19Neoplasm Metastasis 17Colorectal Neoplasms 17Ovarian Neoplasms 15Lymphoma, Non-Hodgkin 15Carcinoma, Renal Cell 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Myelodysplastic Syndromes 11Lung Neoplasms 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Lymphoma, Mantle-Cell 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Adenocarcinoma 9Thyroid Neoplasms 8

Interventions

Gemcitabine 2Cisplatin 2Carboplatin 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has announcements × Urothelial Cancer × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡